Recommendations for the treatment of severe in-hospital pneumonia;Recomendaciones para el tratamiento de la neumonía intrahospitalaria grave

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 8, 2004, Pages 471-485

  Jorda Marcos R ^a   Torres Marti A ^b   Ariza Cardenal, F J ^b   Alvarez Lerma F ^b   Barcenilla Gaite, F ^b  

^a Clinica Rotger   (Spain)

^b NONE

Author keywords

Antibiotics; Nosocomial infection; Pneumonia; Recommendations; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; MEROPENEM; NEOMYCIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DISEASE COURSE; DRUG USE; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; PATIENT CODING; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SCORING SYSTEM; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 8644255091     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13066855     Document Type: Review

References (103)

1. Álvarez Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22:387-94.
2. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
3. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27:355-62.
4. Celis R, Torres A, Gatell JM, Almela M, Rodríguez-Roisin R, Agustí-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93:318-24.
5. Torres A, Aznar, R, Gatell JM. Jiménez P, González J, Ferrer A, et al. Incidence risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990;142:523-8.
6. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
7. Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia: Executive summary. Chest 2000;117:177S-81S.
8. Campbell G, Niederman M, Broughton W, Craven D, Fein A, Fink M, et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996;153:1711-25.
9. Torres A, De Celis MR, Bello S, Blanquer J, Dorca J, Molinos L, et al. Normativas SEPAR. Diagnóstico y tratamiento de la neumonía nosocomial. Arch Bronconeumol 1997;33:346-50.
10. Niederman MS, Bass JB Jr., Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
11. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-9.
12. Torres A, Carlet J. Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia. Eur Respir J 2001;17:1034-45.
13. Drakulovic MB, Bauer TT, Torres A, González J, Rodríguez MJ, Angrill J. Initial bacterial colonization in patients admitted to a respiratory intensive care unit: bacteriological pattern and risk factors. Respiration 2001;68:58-66.
14. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999;160:608-13.
15. Rello J, Rodríguez R, Jubert P, Álvarez B. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996;23:723-8.
16. Rello J, Rue M, Jubert P, Muses G, Sonora R, Vallés J, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997;25:1862-7.
17. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, et al. International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia. Chest 2001;120:955-70.
18. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
19. Franklin C, Henrickson K, Wail M. Reduced mortality of pneumococcal bacteremia after early intensive care. J Intensive Care 1994;6:302-7.
20. Álvarez-Lerma F, Torres A, Rodriguez de Castro F. Recomendaciones para el diagnóstico de la neumonía asociada a ventilación mecánica. Enferm Infecc Microbiol Clin 2001;19:479-87.
21. Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Pronostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995;107:511-6.
22. Berrouane Y, Daudenthun I, Riegel B, Emery MN, Martin G, Krivosic R, et al. Early onset pneumonia in neurosurgical intensive care unit patients. J Hosp Infect 1998;40:275-80.
23. Rello J, Ausina V, Ricart M, Puzo C, Net A, Prats G. Nosocomial pneumonia in critically ill comatose patients: need for a differential therapeutic approach. Eur Respir J 1992;5:1249-53.
24. Cazzadori A, Di Perri G, Vento S, Bonora S, Fendt D, Rossi M, et al. Aetiology of pneumonia following isolated closed head injury. Respir Med 1997; 91:193-9.
25. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249-56.
26. Rodríguez JL, Gibbons KJ, Bitzer LG, Dechert RE, Steinberg SM, Flint LM. Pneumonia: incidence, risk factors, and outcome in injured patients. J Trauma 1991;31:907-12.
27. Mandell LA, Campbell GD Jr. Nosocomial pneumonia guidelines: an international perspective. Chest 1998;113:188S-93S.
28. Fink MP, Snydman DR, Niederman MS, Leeper KV Jr., Johnson RH, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994;38:547-57.
29. García-Rodríguez JA, Baquero F, García de Lomas J, Aguilar L. Antimicrobial susceptibility of 1.422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens. Infection 1999;27:265-7.
30. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin Infect Dis 2000;31:S16-23.
31. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485-506.
32. Brown EM. Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia. J Antimicrob Chemother 1997;40:463-8.
33. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-13.
34. Manhold C, Von Rolbicki U, Brase R, Timm J, Von Pritzbuer E, Heimesaat M, et al. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 1998;24:1327-30.
35. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
36. Korvick JA, Bryan CS, Farber B, Beam TR, Jr., Schenfeld L, Muder RR, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36:2639-44.
37. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
38. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 1995;9:497-530.
39. Radberg G, Nilsson LE, Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother 1990;34:2142-7.
40. Gilbert DN. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis 1997;24:816-9.
41. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Brit Med J 1996;312:338-45.
42. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996;40:691-5.
43. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
44. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
45. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26:31-9.
46. Bressolle F, De la Coussaye JE, Ayoub R, Fabre D, Gomeni R, Saissi G, et al. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992;36:1404-11.
47. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.
48. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98.
49. Álvarez-Lerma F, Palomar M, Olaechea P, Insausti J, Bermejo B, Cerdá E. Estudio nacional de vigilancia de infección nosocomial en unidades de cuidados intensives. Informe del año 2001. Med Intensive 2003;27:13-23.
50. Bou G. El alto nivel de resistencia a los carbapenems en Acinetobacter baumannii es un problema multifactorial. Enferm Infecc Microbiol Clin 2001;19:336-8.
51. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant Acinetobacter baumanii ventilator- associated penumonia (VAP) with intravenous colistin. Clin Infect Dis 2003;36:1111-8.
52. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-52.
53. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996;24:380-8.
54. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-40.
55. Torres A, Aznar R, Gatell JM, Jiménez P, González J, Ferrer A, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990;142:523-8.
56. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996;23:538-42.
57. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-29.
58. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
59. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17:497-504.
60. Yokochi T, Kusumi A, Kido N, Kato Y, Sugiyama T, Koide N, et al. Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide. Antimicrob Agents Chemother 1996;40:2410-2.
61. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-72.
62. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40:677-83.
63. Boucher BA. Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient. Am J Surg 2000;179:45-50.
64. Lode H, Raffenberg M, Geerdes-Fenge H. Monotherapy of nosocomial pneumonia. Sem Resp Crit Care Med 2000;21:9-17.
65. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-30.
66. Cole PJ. The role of nebulized antibiotics in treating serious respiratory infections. J Chemother 2001;13:354-62.
67. Rello J, Diaz E, Bodi M. Appropriate antibiotic treatment for pneumonia. Clin Infect Dis 2000;31:1313-5.
68. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40:696-700.
69. Shirai M, Ide K, Sato M, Murakami M, Tanaka Y, Sato A, et al. [Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus]. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:1233-9.
70. Kahata K, Hashino S, Imamura M, Mori A, Kobayashi S, Asaka M. Inhaled vancomycin-induced allergic reaction in decontamination of respiratory tracts for allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;20:1001-3.
71. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
72. Álvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985;28:689-90.
73. Kimura A, Mochizuki T, Nishizawa K, Mashiko K, Yamamoto Y, Otsuka T. Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998;45:383-7.
74. Quinupristin/dalfopristin. Med Lett Drugs Ther 1999;41:109-10.
75. Fuchs PC, Barry AL, Brown SD. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal. Antimicrob Agents Chemother 2001;45:2662-5.
76. Betriu C, Redondo M, Boloix A, Gómez M, Culebras E, Picazo JJ. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001;48:911-3.
77. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161:753-62.
78. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
79. Chow JW, Davidson A, Sanford E 3rd, Zervos MJ. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997;24:91-2.
80. Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother 2000;44:1394-6.
81. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999;43:1747-53.
82. Totsuka K, Shiseki M, Kikuchi K, Matsui Y. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. J Antimicrob Chemother 1999;44:455-60.
83. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000;44:3055-60.
84. Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000;162:119-25.
85. Meduri GU, Mauldin GL, Wunderink RG, Leeper KV Jr., Jones CB, Tolley E, et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 1994;106:221-35.
86. Jorda R, Parras F, Ibáñez J, Reina J, Bergada J, Raurich JM. Diagnosis of nosocomial pneumonia in mechanically ventilated patients by the blind protected telescoping catheter. Intensive Care Med 1993;19:377-82.
87. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11.
88. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9.
89. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676-82.
90. Wunderink RG. Ventilator-associated pneumonia. Failure to respond to antibiotic therapy. Clin Chest Med 1995;16:173-93.
91. Niederman MS. Bronchoscopy in nonresolving nosocomial pneumonia. Chest 2000;117:212S-8S.
92. Lowenkron S, Fein A. The 10 most common questions about nonresolving pneumonia. Clin Pulm Med 1995;2:88-97.
93. Kuru T, Lynch JP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999;20:623-51.
94. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001;85:1511-30.
95. Dennesen PJ, Van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371-5.
96. Rello J, Mariscal D, March F, Jubert P, Sánchez F, Vallés J, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998;157:912-6.
97. Silver DR, Cohen IL, Weinberg PF. Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. Chest 1992;101:194-8.
98. Rowe S, Cheadle WG. Complications of nosocomial pneumonia in the surgical patient. Am J Surg 2000;179:63-8.
99. Álvarez Lerma F, Palomar M. Decálogo de normas para la utilization de antibióticos en pacientes críticos. Med Intensiva 2000;24:69-77.
100. Slattery JT. A pharmacokinetic model-independent approach for estimating dose required to give desired steady-state trough concentrations of drug in plasma. J Pharmacokinet Biopharm 1980;8:105-10.
101. Álvarez Lerma F. Impacto de las resistencias bacterianas sobre la politica antibiótica. Med Intensiva 1998;22:17-23.
102. Kosmidis J, Koratzanis G. Emergence of resistant bacterial strains during treatment of infections in the respiratory tract. Scand J Infect Dis Suppl 1986;49:135-9.
103. Dworzack DL, Pugsley MP, Sanders CC, Horowitz EA. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol 1987;6:456-9.